PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Non-public fairness investor BC Investments IV on Tuesday bought a stake value Rs 612 crore in Emcure Pharma by means...
Non-public fairness investor BC Investments IV on Tuesday bought a stake value Rs 612 crore in Emcure Pharma by means...
Gland Pharma has gained 19% on the bourses previously three buying and selling periods to hit a 52-week excessive after...
Solar Pharma on Saturday reported a 15% enhance in its third quarter gross sales to Rs 15,469 crore, whereas web...
Hello, you’re listening to ET Markets Radio, I’m your host Neha Vashishth. Welcome to a contemporary episode of ET Market...
Markets traded in a slim vary and ended practically flat on Friday. In in the present day's commerce, shares of...
Sunil Singhania, founding father of Abakkus Asset Supervisor LLP, has suggested buyers to remain cautious on IT providers shares whereas...
Hello, you’re listening to ET Market Watch. I’m Neha Vashishth Mahajan, right here’s a fast wrap of the market motion...
NEW DELHI: The Nifty Pharma index closed on a optimistic word on Monday. Shares of Mankind Pharma Ltd.(up 4.59 per...
EID Parry is presently forming a Greater Excessive, Greater Low construction, suggesting an ongoing uptrend. Nonetheless, the inventory has surged...
NEW DELHI: The Nifty Pharma index traded damaging round 11:03AM(IST)on Tuesday in a weak market. Glenmark Prescribed drugs Ltd.(up 1.61...
PE agency Introduction backed Suven Pharma internet revenue rose 78% year-on-year (YoY) to Rs 83.3 crore in Q3FY25 in comparison...
(Reuters) - Gilead Sciences (NASDAQ:) mentioned on Saturday that it entered right into a partnership with Denmark's LEO Pharma to...
Shares of Piramal Pharma soared 8.3% to their day’s excessive of Rs 272 on the BSE after the home brokerage...
Indian benchmark indices fell like a pack of playing cards on Thursday on the again of serious promoting stress in...
Brokerage UBS prefers Solar Pharma and Cipla amongst Indian drugmakers and expects the shares to return 26% and 23%, respectively,...